Dr. Cardin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3601 21st Ave S
Nashville, TN 37232Phone+1 615-322-3000Fax+1 615-936-0605
Summary
- Dr. Dana Cardin is an oncologist in Nashville, TN and is affiliated with Vanderbilt University Medical Center. She received her medical degree from University of North Carolina at Chapel Hill School of Medicine and has been in practice 14 years. She specializes in gastrointestinal cancer and pancreas cancer clinical trials.
Education & Training
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009- Vanderbilt University Medical CenterResidency, Internal Medicine, 2004 - 2006
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalInternship, Internal Medicine, 2003 - 2004
University of North Carolina at Chapel Hill School of MedicineClass of 2003
Certifications & Licensure
TN State Medical License 2005 - 2026
AL State Medical License 2020 - 2020- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2012 Jul 30
- Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer Start of enrollment: 2013 May 01
- S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Start of enrollment: 2016 Jan 06
- Join now to see all
Publications & Presentations
PubMed
- Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study.Erkut H Borazanci, Nathan Bahary, Vincent Chung, Timothy K Huyck, Ebenezer A Kio
The Oncologist. 2024-11-04 - 17 citationsAmpullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.E Gabriela Chiorean, Marco Del Chiaro, Margaret A Tempero, Mokenge P Malafa, Al B Benson
Journal of the National Comprehensive Cancer Network. 2023-07-01 - 31 citationsFirst-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.Elizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, Daniel C Cho, Sarah P Blagden
Journal for Immunotherapy of Cancer. 2022-10-01
Lectures
- Pilot study to test safety and efficacy of avelumab in small bowel adenocarcinoma (SBA).ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
Clinical Score Can Guide PRRT Therapy Decisions for Neuroendocrine TumorsJanuary 19th, 2022
Moonshot to Cure Cancer Initiative Hailed as Tipping PointJanuary 15th, 2016
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
